Market Signal Briefing

Shares of United-Guardian, Inc. (UG - Free Report) have declined 10% since reporting earnings for the third quarter of 2025. This compares with the S&P 500 index’s 0.6% rise over the same time frame. Over the past month, the stock has lost 16% compared with the S&P 500’s 1.5% fall.

For the quarter ended Sept. 30, 2025, United-Guardian’s net sales fell 26% to $2.26 million from $3.06 million a year earlier. Net income dropped to $268,441 from $865,484, with earnings per share plummeting 68% to 6 cents from 19 cents. For the first nine months of 2025, net sales declined 22% to $7.58 million from $9.71 million, while net income fell to $1.46 million from $2.75 million, and the EPS decreased about 47% to 32 cents from 60 cents.

Revenue Mix & Other Key MetricsThe weakness in the quarter was concentrated in United-Guardian’s cosmetic ingredients business, which management identifies as the main driver of the year-over-year sales decline. In contrast, the company reported that sales of pharmaceutical products and medical lubricants increased 10% and 6%, respectively, over the first nine months of 2025 compared with the same period of 2024.

Management links the cosmetic softness to reduced purchases by Ashland Specialty Ingredients (“ASI”), the company’s largest marketing partner for cosmetic ingredients. ASI has been contending with tariff and geopolitical challenges in Asia, which have encouraged some end-customers to shift toward lower-priced local suppliers. As a result, ASI has been working down excess inventory and has ordered less from United-Guardian this year, weighing heavily on the cosmetics category and UG’s overall sales.

United-Guardian mentioned that these pressures translated into lower income from operations, which fell to $215,072 in the quarter from $949,128 a year earlier, and to $1.52 million for the nine months from $3.09 million in 2024. Other income, including investment income and gains on marketable securities, also declined modestly year over year, dampening the bottom-line results.

Management Commentary & Strategic InitiativesUnited-Guardian’s president Donna Vigilante emphasized that the company still sees underlying strength in its pharmaceutical and medical businesses despite the cosmetic headwinds. She noted that ASI is confident that it would be able to regain market share by offering more competitive pricing, suggesting that some of the current weakness could be cyclical and tied to channel destocking.

Management also highlighted several growth initiatives. A key focus is on Renacidin, the company’s most important pharmaceutical product. United-Guardian is working with an external pharmaceutical consultant to secure placement of Renacidin on additional drug formularies, which it believes can “significantly increase sales” over the coming years.

Beyond pharmaceuticals, the company’s MD&A outlines steps taken to expand its sexual wellness and personal care portfolio. United-Guardian entered a strategic distribution arrangement with Brenntag Specialties in late 2023 to support a new line of sexual wellness ingredients in the United States and several international markets, and it has expanded its relationship with Azelis Group in Europe and is adding South Korea as a territory for another distributor. These moves are intended to diversify revenue sources and broaden the company’s geographic reach.

Factors Behind Margin & Earnings PressureThere are several factors that compressed profitability in the latest quarter. Cost of sales increased as a percentage of net sales, reflecting both product-mix shifts and a challenging pricing environment. With cosmetic ingredients — a historically important contributor — under pressure, the company faced a less favorable margin mix and greater reliance on lower-margin product lines.

Operating expenses rose year over year, in part due to higher professional fees and other corporate expenses. Research and development spending also increased from the prior-year quarter and in the past nine months, as United-Guardian continued to fund product initiatives. While these investments may support longer-term growth, they added to the near-term drag on earnings.

Other income items provided less support than in 2024. Investment income and gains on marketable securities were lower in the quarter and for the first nine months of 2025, moderating the contribution from the company’s sizable cash and marketable securities portfolio. The effective tax rate was around 20%, similar to the prior year. Therefore, tax effects did not offset the operational shortfall in any meaningful way.

ViewUnited-Guardian did not issue numerical guidance for the remainder of 2025. However, management’s comments point to a cautiously optimistic outlook. The company is counting on ASI’s efforts to restore competitiveness and market share in Asia, and its distribution expansions to stabilize and eventually grow cosmetic ingredients sales. At the same time, management is focused on building Renacidin into a larger revenue contributor through expanded formulary access and on leveraging new marketing agreements for its personal care products.

While these initiatives are still in progress and subject to the usual industry and macroeconomic risks, they suggest that the current earnings weakness is driven more by external demand and channel-inventory dynamics than by an erosion of the company’s product portfolio.

Other DevelopmentsUnited-Guardian continued its longstanding practice of returning cash to shareholders through dividends, declaring and paying out cash dividends during the first nine months of 2025, including a 35 cents per share dividend earlier in the year.

SummaryMercury Systems delivered strong Q1 results, driven by a $20M sales pull-forward, higher-margin backlog, and operational improvements.MRCY expects near-term revenue softness but forecasts robust margin and EBITDA growth through FY28, supported by automation and expanding defense demand.The price target is adjusted slightly to $84.49, with long-term upside supported by improved EBITDA, free cash flow, and a $200M share buyback program.I reiterate a buy rating on MRCY, citing management confidence, higher-quality revenues, and efficiency gains as key drivers for future growth. William_Potter/iStock via Getty Images

Mercury Systems (NASDAQ:MRCY) stock has advanced nearly 12% since my buy rating in August, outperforming the S&P 500’s 4.4% gain. The defense electronics specialist is enjoying the benefits of revenue growth, a higher margin backlog flowing into the sales window, and automation. In

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Fast food giant Wendy’s plans to close hundreds of its U.S. stores next year as part of a broader effort to revive its domestic business, which has been under pressure from slowing sales.

Interim CEO Ken Cook said during the company's earnings call on Friday that a "mid-single-digit percentage" of its 6,011 U.S. restaurants are expected to close next year. A mid-single-digit percentage is about 4% to 6%, which means the least number of closures would be 241 stores. 

FOX Business reached out to Wendy's for comment. 

MCDONALD’S BRINGS BACK EXTRA VALUE MEALS TO LURE BUDGET-CONSCIOUS CUSTOMERS 

This comes as Wendy’s executives said that its business and sales "remain under pressure" and that it is "acting with urgency" to return sales at its U.S. stores to growth. 

In its latest fiscal quarter, global sales were down 2.6% and sales at U.S. locations fell 4.7%. The company blamed the drop in U.S. sales largely on fewer customer visits, though this was partially offset by higher spending per order.

Interim CEO Ken Cook said during the company's earnings call on Friday that a "mid-single-digit percentage" of its 6,011 U.S. restaurants are expected to close next year. (Al Drago/Bloomberg via Getty Images / Getty Images)

MCDONALD’S CEO WARNS RISING BEEF PRICES REMAIN A CHALLENGE AS INFLATION STAYS ‘STICKY’

However, the company said in its earnings call that it is making "meaningful progress on key actions to enhance the customer experience" and that it is seeing this payoff in its U.S. company-operated restaurants. Earlier this year, the company said it was working on simplifying its programming and execution.

Rather than adding more stores, the company is trying to focus on increasing sales at each U.S. location. To do this, Wendy's launched Project Fresh, a major plan that was designed to improve performance, boost its profits and ensure viability.  

Wendy’s executives said that its business and sales "remain under pressure." (Justin Sullivan/Getty Images)

KFC BRINGS BACK A TASTE OF NOSTALGIA WITH FAN-FAVORITE ITEM

Wendy's story isn't unique. In fact, the entire quick-service restaurant sector has come under pressure as its core customers feel strained by higher living costs, which are shrinking their discretionary income. This has forced many industry giants to ramp up promotions in an effort to drive more traffic.

Rather than adding more stores, the company is trying to focus on increasing sales at each U.S. location. (Daniel Acker/Bloomberg)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Will Auchincloss, who serves as the EY‑Parthenon's Americas retail sector leader, previously told FOX Business that its consumer research points to the fact that Americans are beginning to adjust discretionary spending to offset rising costs for essential goods and services like food and housing. Restaurant spending, across all income cohorts, is the first to take a hit, he said. 

Ticker Security Last Change Change % WEN THE WENDY'S CO. 8.54 -0.43
-4.79%
"With nearly 40% of lower-income households already pulling back, recent QSR [quick-service restaurant] price cuts may be a signal of a broader industry shift," he said, adding that "brands are facing mounting pressure from value-conscious consumers, and if this trend accelerates, we could see a realignment of pricing strategies across the sector."

Repligen Corporation (RGEN) Stifel 2025 Healthcare Conference November 11, 2025 10:00 AM EST

Company Participants

Olivier Loeillot - President, CEO & Director

Conference Call Participants

Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Daniel Arias
Stifel, Nicolaus & Company, Incorporated, Research Division

I'm wrapping up the quarter for a lot of these sessions. As a kickoff, for Repligen, it was a good quarter. It was 18% organic growth. Each of the key product areas was up double digits. Op margins were 14.2%, down 70 bps and then you beat the streak by $0.05 on the bottom line.

Question-and-Answer Session

Daniel Arias
Stifel, Nicolaus & Company, Incorporated, Research Division

Maybe just talk a little bit about what got you there and what you think about where the various components of the business are right now?

Olivier Loeillot
President, CEO & Director

Yes. No, absolutely, Daniel. You're right. We are obviously very happy about our quarter 3 results. I mean, year-to-date non-COVID organic growth of 16%. So obviously, we are delighted about that. And what I think is really important is to figuring out we really have that broad and innovative portfolio of products. Sometimes people have a tendency to summarize our business in one single product line, but we are very diverse. And quarter 3 was a showcase here where really the 2 franchises that over delivered were analytics and protein and which was not completely expected to be very open here, but that was really a good surprise. And again, the breadth of our portfolio is a testimony of how we can grow faster than market. We've always said we want to grow more than 5% above market growth. And this year, we're probably going to be significantly above that.

And then in terms of market

Recommended For You

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2026 in the securities class action first filed by the Firm.

So What: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Telix class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the Case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materially overstated the quality of Telix's supply chain and partners; and (3) as a result, defendants' statements about Telix's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Telix class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the “Class Period”), of the important December 2, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Molina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Molina class action, go to https://rosenlegal.com/submit-form/?case_id=45913 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 2, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period failed to disclose to investors: (1) material, adverse facts concerning Molina’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) as a result of the foregoing, defendants’ positive statements about Molina’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Molina class action, go to https://rosenlegal.com/submit-form/?case_id=45913 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Visa Inc (NYSE:V, ETR:3V64) and Mastercard Inc (NYSE:MA) have reached a proposed settlement with US merchants aimed at resolving more than two decades of litigation over credit card interchange fees and merchant rules, a deal that could reshape how retailers manage payment costs and how consumers are charged at checkout.

The agreement would reduce the average effective interchange fee merchants pay on US credit card transactions by roughly 10 basis points, or 0.1 percentage point, for five years.

The change, while modest in scale compared to typical fee levels of around 2% to 2.5%, could translate into billions of dollars in potential savings across millions of transactions.

Under the settlement, merchants would also gain greater flexibility in how they handle card payments. They could impose surcharges of up to 3% on Visa or Mastercard transactions, even if they do not apply such fees to cards from other networks.

In addition, the long-standing “honor all cards” rule, which required merchants to accept all Visa or Mastercard credit cards if they accepted any, would be relaxed. Merchants could now choose whether to accept premium or business cards within each network, though they must still treat all issuers equally within a card category.

The deal, which still requires approval from a federal judge, is expected to take effect in late 2026 or early 2027.

Analysts at USB said the proposed agreement moves Visa and Mastercard closer to resolving a major legal overhang without directly affecting their core network fees.

“This settlement follows approximately 20 years of litigation, including a prior March 2024 settlement that was rejected by the Court in June 2024, as well as monetary damages previously settled and/or expected to be settled,” they noted.  

The analysts added that Visa and Mastercard’s concessions, including surcharging flexibility and allowing merchants to form collective buying groups, are significant from a policy standpoint but limited in financial impact.

Shares of Visa added 1.2% at about $339 on the deal, while Mastercard stock was up 0.8% at $558.

$5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of Warrants

November 11, 2025 15:31 ET

 | Source:

PDS Biotechnology Corporation

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,800,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.91 per share and accompanying warrants to purchase up to an aggregate of 5,800,000 shares of its common stock in a registered direct offering (the “Offering”). The warrants will have an exercise price of $1.00 per share, will be exercisable beginning six months after issuance and will expire five years from the initial exercise date. The Offering is expected to close on or about November 12, 2025, subject to the satisfaction of customary closing conditions.

Craig-Hallum is acting as the exclusive placement agent for the offering.

The initial gross proceeds to the Company from the Offering are expected to be approximately $5.3 million, before deducting the placement agent’s fees and other offering expenses payable by the Company upon the closing of the Offering and up to an additional $5.8 million may be funded upon the full cash exercise of the warrants. The Company currently intends to use the net proceeds from the offering for the continuation of its ongoing VERSATILE-003 Phase 3 clinical trial following planned discussions with the Food and Drug Administration (FDA) regarding an amendment to the trial’s protocol, that would allow for an expedited approval pathway for PDS0101 and for other research and development expenses and general corporate purposes.

For the three month period ended September 30, 2025, the Company had approximately $26.2 million of cash and cash equivalents. This is derived from the Company’s internal books and records and is subject to the completion of financial closing procedures, final adjustments and other developments which may arise between now and the time the financial results for the quarter ended September 30, 2025 are finalized. Therefore, actual results may differ materially from this estimate, and all of the preliminary estimates are subject to change. In addition, preliminary unaudited financial information for the Company’s three month period ended September 30, 2025 is not necessarily indicative of operating results for any future period.

The Offering is being made pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-267041), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 24, 2022 and declared effective by the SEC on September 2, 2022. The offering of the securities to be issued in the Offering are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 North Washington Ave., Minneapolis, MN 55401, by telephone at (612) 334-6300 or by email at [email protected].

The Company also has agreed to amend certain existing warrants to purchase up to an aggregate of 5,948,334 shares of the Company’s common stock that were previously issued to investors in February 2025, with an exercise price of $1.50 per share, effective upon the closing of the Offering, such that the amended warrants will have a reduced exercise price of $1.00 per share and will be exercisable beginning six months after the closing of the Offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy PDS0101 (Versamune® HPV) is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. PDS01ADC is being evaluated in multiple phase 2 trials in various cancer indications in combination with standard of care.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation and other matters, including, without limitation, statements regarding the consummation of the Offering, the satisfaction of closing conditions and the use of proceeds from the Offering. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0101 (Versamune® HPV), PDS01ADC, PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 (Versamune® HPV), PDS01ADC, PDS0103 (Versamune® MUC1) and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Versamune® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:

Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: [email protected]

Media Contact:

David Schull
Russo Partners
Phone +1 (858) 717-2310
Email: [email protected]

Q3: 2025-11-10 Earnings SummaryEPS of $0.34 beats by $0.10

 |

Revenue of

$35.12M

(5.18% Y/Y)

beats by $2.22M

Consolidated Water Co. Ltd. (CWCO) Q3 2025 Earnings Call November 11, 2025 11:00 AM EST

Company Participants

Frederick McTaggart - CEO, President & Director
David Sasnett - Executive VP & CFO

Conference Call Participants

Gerard Sweeney - ROTH Capital Partners, LLC, Research Division

Presentation

Operator

Good morning. Thank you for joining us today to discuss Consolidated Water Company's third quarter 2025 operating and financial results. Hosting the call today is the Chief Executive Officer of Consolidated Water, Rick McTaggart; and the company's Chief Financial Officer, David Sasnett. Following their remarks, we'll open the call to your questions.

[Operator Instructions] Before we conclude today's call, I'll provide some important cautions regarding the forward-looking statements made by management during the call. I'd like to remind everyone that today's call is being recorded, and it will be made available for telecom replay. Please see the instructions in yesterday's press release that has been posted to the Investor Relations section of the company's website.

Now I'd like to turn the call over to Consolidated Water's CEO, Rick McTaggart. Sir, please go ahead.

Frederick McTaggart
CEO, President & Director

Thank you, Chloe, and good morning, everyone. Thank you for joining us today to discuss our financial and operating results for our third quarter of 2025.

In the third quarter, our diversified water business model, which encompasses regulated utility operations, design and construction services, O&M services, and manufacturing continued to deliver strong performance. This steady progress led to a notable increase in overall revenue and earnings per share from our continuing operations compared to the same period last year.

Retail water sales in the exclusive utility service area on Grand Cayman were higher than the previous year because of ongoing strength of the economy in the Cayman Islands and drier weather conditions on Grand Cayman. We

Recommended For You

November 11, 2025 3:33 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Quanex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at the time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Quanex's procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly "underinvested"; (2) as a result, Quanex's tooling and equipment conditions had significantly degraded to near "catastrophic" levels; (3) as a result of the foregoing, Quanex was likely to incur significant costs, "pushing out the timing" of expected benefits from the Tyman integration; (4) Quanex had previously identified the foregoing issues; and (5) as a result of the foregoing, defendants' positive statements about Quanex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274031

Chainlink (LINK) is facing continuous bearish pressure, struggling to break key resistance. Market analyst GainMuse notes a series of lower highs, highlighting persistent seller dominance and stalled recovery attempts.

Notably, Chainlink’s attempts to recover from the $17–$17.5 zone have repeatedly failed, turning a potential support area into a strong resistance level.

Each rebound has been met with selling pressure, keeping LINK trapped below key resistance and stalling any bullish momentum.

What does this mean? Technical patterns indicate a clear bearish bias. A series of lower highs signals weakening buyer momentum, as each rally fails to reach the prior peaks. This diminishing investor appetite often foreshadows further declines, as sellers consolidate control over the market.

Therefore, LINK’s failure to hold the $17–$17.5 recovery zone highlights the market’s heightened sensitivity, where even minor news triggers sharp moves amid prevailing bearish sentiment. The cryptocurrency now trades at $15.73.

Advertisement
 

UBS Executes World’s First Live Tokenised Fund Transaction via Chainlink DTA
UBS, managing over $6 trillion in assets, has completed the world’s first live tokenised fund transaction using Chainlink’s Digital Transfer Agent (DTA) standard, proving that complex fund operations can now run entirely on-chain under real market conditions.

UBS’s adoption of the Chainlink DTA standard marks a major leap in integrating blockchain into traditional finance. 

The tokenized system digitizes fund share issuance, transfer, and redemption, delivering instant settlement, automated compliance, and fully auditable on-chain transactions, streamlining processes that once relied on manual reconciliation and intermediaries.

The rise of tokenized funds signals a shift in bridging traditional finance with decentralized technologies. For UBS, this move goes beyond a proof of concept, it’s a strategic step to modernize fund operations, reduce risk, streamline workflows, cut costs, and enable faster, more secure cross-border transactions for institutional and private clients.

What’s unique about Chainlink’s DTA standard? Well, it bridges traditional finance and blockchain by ensuring regulatory compliance while delivering the speed, transparency, and efficiency of on-chain transactions. This enables fund managers to execute tokenized funds at scale without compromising on legal requirements, removing a key barrier to institutional adoption.

Meanwhile, on-chain analytics firm Santiment recently reported that Chainlink has strengthened its lead in DeFi development, further distancing itself from competitors.

XRP is trading at $2.42 to $2.437 over the last hour as of Nov. 11, 2025, down 5% on the day but still clinging to an 8% gain for the week. The cryptocurrency's market capitalization hovers at $145 billion, backed by a decent 24-hour trading volume of $4.45 billion.

In a recent social media post, Ethereum co-founder Vitalik Buterin has opined that in the future, when anti-aging therapies or significant lifespan/healthspan extensions exist, people will look back at our current era and be shocked that we tolerated age-related deaths as "normal." 

The prominent Canadian developer believes that aging is a preventable problem.

The billionaire often combines tech optimism, long-term thinking, and effective altruism as part of his philosophy.

HOT Stories

In early 2018, he donated roughly $2.4 million in Ether to the SENS Research Foundation, a nonprofit focused on the biomedical research of rejuvenation therapies. 

Buterin has previously described aging as "one of the greatest problems facing humanity." 

Back in 2020, the cryptocurrency luminary predicted that there would be a shift toward biotech. The "final boss": massively extending healthy life-span and ending aging entirely.

"So like basically, you know, just imagine the concept of your grandmother dying, just kind of slowly and imperceptibly disappearing from the public consciousness over the course of around 40 years…" Buterin said during a podcast appearance back in 2021. 

Fighting aging Buterin is, of course, far from being the only prominent executive who is advocating against aging.  There are several other tech executives and prominent figures known for their strong interest in anti‑aging or longevity research.

For instance, Bryan Johnson, founder of companies like Kernel and Braintree, famously runs a highly publicised anti‑aging program called "Project Blueprint." It involves an intense diet, supplements, and biomarkers. 

Billionaire Peter Thiel, who is also known as a prominent crypto investor,  has invested heavily in companies addressing aging and life extension. He has donated millions to longevity research via foundations like the Methuselah Foundation. 

OpenAI CEO Sam Altman has also been actively investing in longevity research. 

Ethereum is once again testing a major resistance level that could define its next big move. After a steady recovery from recent lows, ETH has approached the $3,700 zone, a price area that traders view as the dividing line between bullish continuation and potential reversal.

According to market analyst Ali Martinez, XRP whales have offloaded roughly 900,000 coins in just five days, a move that may signal shifting short-term sentiment.

On-chain data indicates these large holders could be taking profits from recent price gains or repositioning ahead of expected market volatility.

Source: Ali Martinez
Notably, whale behavior typically cycles between accumulation and profit-taking, with large holders shifting assets for treasury management, portfolio rebalancing, or strategic selling.

Therefore, the recent offloading of 900,000 XRP by major holders signals rising caution among whales. Though not an outright bearish indicator, it adds a critical layer of uncertainty to XRP’s market structure.

Ripple’s RLUSD Stablecoin Surpasses $1 Billion Market Cap
Ripple’s U.S. dollar-backed stablecoin, RLUSD, recently surpassed $1 billion in market capitalization, marking a significant milestone in the company’s expanding role within the digital asset ecosystem, per CryptoQuant data.

Advertisement
 

Source: CryptoQuant
Additionally, CoinMarketCap data showed RLUSD’s circulating supply reaching 1.02 billion tokens, split across the Ethereum and XRP Ledger (XRPL) networks.

Notably, the dual-chain issuance highlights Ripple’s commitment to cross-network interoperability and institutional-grade liquidity, reinforcing its mission to unite traditional finance with blockchain innovation.

Deploying RLUSD on Ethereum unlocks access to the world’s most active DeFi ecosystem, while XRPL integration delivers ultra-fast, low-cost transactions, a strategic edge for global payments and remittances.

Therefore, RLUSD’s rapid growth could become a key driver of Ripple’s ecosystem expansion. Its dual-chain interoperability across Ethereum and XRPL gives it a clear edge over single-chain stablecoins, enabling smoother liquidity flows across DEXs, payment platforms, and cross-border settlement networks.

Meanwhile, Ripple recently secured $500 million in a strategic round led by Fortress Investment Group, propelling its valuation to an impressive $40 billion.

Key takeaways:

Solana’s strong onchain metrics and DApps revenue dominance hint at long-term strength despite recent selling pressure from major holders.

Solana ETF inflows and diversified onchain activity support SOL, yet macro risks in AI and trade remain key obstacles to a $250 recovery.

Solana’s native token, SOL (SOL), fell 6% after flirting with $172 on Monday. The drop largely mirrored a pullback in the Nasdaq Index, which came under pressure after CoreWeave (CRVW US) cut its cloud services revenue forecast and reports surfaced that China plans to ban the US military from accessing its rare-earth minerals. Is there any chance for SOL to reclaim the $250 level in the near term?

SOL/USD (blue) vs. Altcoin market cap (red). Source: TradingView / CointelegraphSOL has underperformed the altcoin market by 7% over the past two weeks, with no clear catalyst for the decline. In fact, the backdrop has been rather encouraging, marked by the debut of a Solana spot exchange-traded fund (ETF) in the US and a notable uptick in Solana’s onchain activity.

Blockchains ranked by 30-day fees. Source: NansenNetwork activity on Solana has surged over the past 30 days, with active addresses increasing by 10% and transactions rising by 8%. By comparison, Ethereum saw 5% fewer active addresses and a 26% drop in transactions during the same period. Hyperliquid, a rising competitor in the decentralized exchange (DEX) space, also experienced a 28% decline in onchain activity.

30-day DApp revenue by chain, USD. Source: DefiLlamaSolana continues to dominate in decentralized applications (DApps) revenue. No other network comes close, giving Solana a sustainable competitive edge. These DApps reward users by sharing part of their earnings as yield, a mechanism that helps the network attract more deposits and reinforce its position.

Solana’s growth shows stronger diversification across multiple sectorsThe total value locked (TVL) on Solana currently stands at $12 billion, widening the gap with BNB Chain, which holds $8 billion. Over the past 30 days, several projects have posted strong gains, including a 35% increase in Securitize (Real World Assets), a 31% rise in Solstice USX (Basis Trading), and a 10% uptick in deposits on Meteora (Liquidity Pools). This data suggests that Solana’s growth is becoming more diversified and less reliant on a single sector.

Weekly DEX volumes by chain, USD. Source: DefiLlamaMemecoin launches and trading activity were once the main forces driving Solana’s user growth and network fees, but that momentum faded by March. While the token has since recovered from its 2025 low of $95, traders remain cautious about its near-term upside.

Since their debut in US markets on Oct. 28, spot Solana ETFs have attracted $343 million in net inflows. Meanwhile, the REX-Osprey SOL + Staking ETF has accumulated an additional $286 million in assets. However, the overall positive effect of these instruments has been partly offset by outflows from companies reducing their SOL holdings.

Solana treasury holdings, SOL. Source: CoinGeckoThe sale of 439,621 SOL by Galaxy Digital Holdings (GLXY) has raised concerns about the sustainability of Solana’s corporate reserve strategy. Forward Industries (FORD) holds the largest position, with 6.82 million SOL, a figure that has remained steady over the past 30 days, according to CoinGecko data.

The odds still favor SOL outperforming the broader altcoin market, supported by Solana’s steady growth in onchain activity and its dominance in DApps revenue. However, the path toward $250 will likely depend on a decline in risks surrounding the artificial intelligence sector and a cooling of geopolitical tensions tied to the ongoing global trade war.

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Key takeaways:

Solana’s strong onchain metrics and DApps revenue dominance hint at long-term strength despite recent selling pressure from major holders.

Solana ETF inflows and diversified onchain activity support SOL, yet macro risks in AI and trade remain key obstacles to a $250 recovery.

Solana’s native token, SOL (SOL), fell 6% after flirting with $172 on Monday. The drop largely mirrored a pullback in the Nasdaq Index, which came under pressure after CoreWeave (CRVW US) cut its cloud services revenue forecast and reports surfaced that China plans to ban the US military from accessing its rare-earth minerals. Is there any chance for SOL to reclaim the $250 level in the near term?

SOL/USD (blue) vs. Altcoin market cap (red). Source: TradingView / CointelegraphSOL has underperformed the altcoin market by 7% over the past two weeks, with no clear catalyst for the decline. In fact, the backdrop has been rather encouraging, marked by the debut of a Solana spot exchange-traded fund (ETF) in the US and a notable uptick in Solana’s onchain activity.

Blockchains ranked by 30-day fees. Source: NansenNetwork activity on Solana has surged over the past 30 days, with active addresses increasing by 10% and transactions rising by 8%. By comparison, Ethereum saw 5% fewer active addresses and a 26% drop in transactions during the same period. Hyperliquid, a rising competitor in the decentralized exchange (DEX) space, also experienced a 28% decline in onchain activity.

30-day DApp revenue by chain, USD. Source: DefiLlamaSolana continues to dominate in decentralized applications (DApps) revenue. No other network comes close, giving Solana a sustainable competitive edge. These DApps reward users by sharing part of their earnings as yield, a mechanism that helps the network attract more deposits and reinforce its position.

Solana’s growth shows stronger diversification across multiple sectorsThe total value locked (TVL) on Solana currently stands at $12 billion, widening the gap with BNB Chain, which holds $8 billion. Over the past 30 days, several projects have posted strong gains, including a 35% increase in Securitize (Real World Assets), a 31% rise in Solstice USX (Basis Trading), and a 10% uptick in deposits on Meteora (Liquidity Pools). This data suggests that Solana’s growth is becoming more diversified and less reliant on a single sector.

Weekly DEX volumes by chain, USD. Source: DefiLlamaMemecoin launches and trading activity were once the main forces driving Solana’s user growth and network fees, but that momentum faded by March. While the token has since recovered from its 2025 low of $95, traders remain cautious about its near-term upside.

Since their debut in US markets on Oct. 28, spot Solana ETFs have attracted $343 million in net inflows. Meanwhile, the REX-Osprey SOL + Staking ETF has accumulated an additional $286 million in assets. However, the overall positive effect of these instruments has been partly offset by outflows from companies reducing their SOL holdings.

Solana treasury holdings, SOL. Source: CoinGeckoThe sale of 439,621 SOL by Galaxy Digital Holdings (GLXY) has raised concerns about the sustainability of Solana’s corporate reserve strategy. Forward Industries (FORD) holds the largest position, with 6.82 million SOL, a figure that has remained steady over the past 30 days, according to CoinGecko data.

The odds still favor SOL outperforming the broader altcoin market, supported by Solana’s steady growth in onchain activity and its dominance in DApps revenue. However, the path toward $250 will likely depend on a decline in risks surrounding the artificial intelligence sector and a cooling of geopolitical tensions tied to the ongoing global trade war.

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

As the market recovers, Bitcoin appears to be displaying renewed bullish strength following several weeks of heightened volatility that caused its price to fall below the $100,000 mark. During this downward trend, many new BTC whales or large holders experienced notable losses, triggering a massive wave of capitulation among these key investors.

New Bitcoin Whales Break Under Pressure
One of Bitcoin’s most influential investor groups: newly formed whale addresses have taken a hit in a market where sentiment is still ambiguous. Bitcoin’s volatile swing in the past few weeks has now sent these key investors’ positions into severe losses, as the price drops below their entry levels. 

MorenoDV, a market expert and author, shared this crucial development in a quick-take post on the CryptoQuant platform after examining the Bitcoin Realized Profits by Whales metric. Specifically, this vital metric helps to determine whether these investors are capitulating (realized losses) or are distributing at a profit (realized gains).

BTC new whales are realizing losses | Source: Chart from CryptoQuant on X
Following the investigation, the expert found that Bitcoin is currently experiencing one of the most aggressive capitulations of the year by new whale entrants. Such a development indicates that the cohort is heavily exiting their positions under pressure, a sign of fear or a dramatic shift in attitude.

Data shows that the new whale investors have realized more than $1.3 billion in losses over the past 6 days, signifying one of 2025’s most aggressive selling campaigns. With significant amounts of BTC being sold at a loss, speculations are whether this is an early signal of deeper weakness in the crypto asset’s short-term price outlook.

What’s Driving The Heightened Selling Pressure Of The Cohort?
According to the expert, sustained losses of this magnitude are indicative of forced selling or panic-driven exits. Meanwhile, this is often caused by the loss of aversion of late entrants or the unwinding of leveraged positions. Given the current bullish state and resilience of the BTC market, MorenoDV stated that this event is a remarkable one.

Despite witnessing one of the biggest capitulation waves among new whales this year, the price of Bitcoin has held between the $100,000 and $105,000 support range so far. In the past, such periods of realized loss concentration have persistently triggered volatility spikes. These spikes either mark local bottoms or lead to extended deleveraging, depending on the market liquidity conditions.

Specifically, the data suggests pain among short-term large holders. However, the capability of the market to absorb this pressure without breaking down may point to underlying demand or accumulation by stronger hands. In the meantime, the expert declares that the upcoming days will help gauge whether this was the last shakeout or a sign of far deeper structural stress.

Providing more data on the trend, CryptoQuant highlighted that Bitcoin has been below the average cost basis of new whales positioned at the $110,800 level since October 28, triggering significant realized losses. The chart displays realized losses of $286.4 million, $90.7 million, $107.5 million, $515.1 million, and $5.1 million on November 4, 5, 6, 7, and 8, respectively.

BTC trading at $104,783 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Pixabay, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

TL;DR

Injective launches its native EVM mainnet, enabling EVM and WASM operations in a unified environment with assets, liquidity, and over 30 ready-to-use dApps.
The platform integrates an institutional liquidity module (CLOB) and the MultiVM Token Standard, ensuring immediate liquidity, token interoperability, and operational security.
Developers can use standard Ethereum tools and plug-and-play financial modules.

Injective launches its native EVM mainnet, marking a key advance in on-chain finance infrastructure. The network allows developers and users to operate on both Ethereum Virtual Machine (EVM) and WebAssembly (WASM) in a unified environment with shared assets, liquidity, and Web3 modules. The platform already supports more than 30 dApps and infrastructure ready for advanced financial application development.

Injective’s testnet processed over 5 billion on-chain transactions across 300,000 unique wallets, validating the network’s capacity to handle high transaction volumes. The native mainnet reduces blockchain frictions: it eliminates platform incompatibilities, accelerates transaction speeds, and lowers fees. In addition, it unifies assets within a single ecosystem.

Key Advantages for Developers
The launch provides a MultiVM environment where EVM and WASM coexist without compromising performance or functionality. Every dApp and token benefits from a shared liquidity layer, enabling smooth and efficient interactions across the ecosystem. Developers can use standard Ethereum development tools such as Hardhat and Foundry without modifications, integrating plug-and-play financial modules that significantly reduce development time.

Injective includes an institutional liquidity module (CLOB), allowing new applications to access high-quality liquidity from day one, eliminating the cold-start problem that limits many platforms. This also enables applications to quickly tokenize and issue real-world assets (RWA), expanding investment and risk management options.

Injective Aims to Create a Circular Process: More dApps, More Developers, More Users, More Liquidity
The MultiVM Token Standard (MTS) ensures that every token has a consistent representation across all dApps, eliminating manual bridges and duplicate token versions. Complex operations execute atomically, protecting user funds and data integrity.

The platform already offers lending markets, tokenized assets, pre-IPO exposure, advanced derivatives, and perpetual futures, along with institutional-grade infrastructure and custody services.

Injective seeks to generate a virtuous cycle: more dApps attract more developers and users, increasing liquidity and activity, which in turn draws new applications and business opportunities.

Injective’s latest upgrade transforms its blockchain into a dual-execution environment, where Ethereum-based applications can run directly on-chain alongside its existing Cosmos-native dApps.

Summary

Injective launches native EVM, enabling Ethereum apps to run alongside Cosmos-native dApps.
Over 30 dApps and infrastructure providers go live on Injective’s upgraded mainnet.

In a statement dated Nov. 11, layer-1 blockchain Injective announced the successful deployment of its native Ethereum Virtual Machine, a core protocol upgrade that fundamentally expands its execution capabilities.

This architectural shift moves beyond simple compatibility, embedding an EVM directly into its state machine and enabling the chain to process Ethereum-native smart contracts and Cosmos-based WebAssembly applications in a single, synchronized environment. The rollout is accompanied by over 30 dApps and infrastructure providers going live on the network from day one, according to the statement.

“This launch represents Injective’s MultiVM vision coming to life. Developers now choose between WebAssembly (WASM) and Ethereum Virtual Machine (EVM) execution, with Solana VM support on the roadmap. This flexibility combined with Injective’s advanced financial modules creates unprecedented opportunities for innovation,” the Injective team said.

Injective’s EVM upgrade tackles blockchain frictions
Injective’s architectural shift is designed to tackle several persistent issues in decentralized finance. The platform addresses industry fragmentation by enabling applications running on different virtual machines to interact seamlessly on a shared liquidity layer. This eliminates the need for complex bridging operations that have often introduced risk and friction for users moving assets between ecosystems.

For developers, the environment offers familiar Ethereum tooling like Hardhat and Foundry, significantly lowering the barrier to entry for teams already skilled in Solidity. This is coupled with what Injective calls its “plug-and-play” financial modules, which provide pre-built components for complex functions like derivatives trading.

At the same time, the network’s shared central limit order book module provides new applications with immediate access to deep, MEV-resistant liquidity from their inception, aiming to solve the notorious “cold start” problem that has stifled many nascent DeFi projects.

Injective’s universal MultiVM Token Standard (MTS) further strengthens the ecosystem by providing a consistent token representation across all dApps. Users no longer face confusion from duplicate token versions or manual bridging, and complex operations execute atomically, preserving both funds and data integrity.

For end users, the practical outcome is access to a broader suite of financial applications without leaving the Injective chain. The statement points to new capabilities, including lending and borrowing markets, tokenized real-world assets, and advanced derivatives, all operating with the network’s characteristic sub-second finality and transaction fees that amount to a fraction of a cent.

Shiba Inu (CRYPTO: SHIB) has been stuck inside tightening price action for months, and the next weekly close will likely determine its direction. Price Compresses Between Multi-Year Trendline And Long-Term Support SHIB Weekly Price Action (Source: TradingView) On the weekly chart, SHIB trades near $0.00000975 to $0.00000980, staying pinned below a descending trendline that has rejected every breakout since October 2021.

Featured

28M CHF Secured by Adam Back and FUTURE for Bitcoin Treasury Project

Tl;DR FUTURE obtuvo 28 millones de francos suizos en nueva financiación. Entre sus directivos se encuentran Adam Back y Richard Byworth. La empresa tiene previsto

Companies

New Smart Contract Language for Bitcoin Unveiled: Blockstream Presents Simplicity

TL;DR: Blockstream launched Simplicity, a Bitcoin-native smart contract language on Liquid sidechain, enabling secure vaults, multi-party controls, and threshold signatures. Its “security-first” design eliminates recursion/infinite

Companies

Blockstream Introduces New Self-Custodial Bitcoin Wallet

TL;DR Enhanced Self-Custody: Blockstream unveils a revamped Bitcoin wallet built on the Blockstream Green platform, enabling users to buy, store, and manage Bitcoin. Robust Security:

Companies

Blockstream to Launch Bitcoin Investment Funds—What to Expect

TL;DR Blockstream is launching three Bitcoin-backed investment funds after securing a multimillion-dollar capital injection, with an official launch set for April 1.  Two funds will

Bitcoin News

Bitcoin (BTC) Market Cap Can Hit $200 Trillion in 9 Years

Adam Back, the co-founder of a company focusing on storing and transferring Bitcoin and other digital assets, Blockstream, believes Bitcoin (BTC) can surge to $10

CryptoCurrency News

Blockstream CEO Adam Back Says CBDCs are Worse Than Bank Accounts

Central Bank Digital Currencies (CBDCs) are becoming more and more common as several countries continue to explore the concept. Many experts believe that these assets

The Investment Committee give you their top stocks to watch for the second half.

Investors might want to bet on Advanced Energy Industries (AEIS - Free Report) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of power-conversion products, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Advanced Energy Industries, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $1.71 per share for the current quarter, which represents a year-over-year change of +31.5%.

Over the last 30 days, the Zacks Consensus Estimate for Advanced Energy has increased 20.59% because two estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsFor the full year, the company is expected to earn $6.13 per share, representing a year-over-year change of +65.2%.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Advanced Energy. Over the past month, four estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 8.08%.

Favorable Zacks RankThe promising estimate revisions have helped Advanced Energy earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineWhile strong estimate revisions for Advanced Energy have attracted decent investments and pushed the stock 20.4% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.